SG Americas Securities LLC Sells 5,473 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

SG Americas Securities LLC reduced its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 33.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,858 shares of the company’s stock after selling 5,473 shares during the quarter. SG Americas Securities LLC’s holdings in Health Catalyst were worth $101,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Point72 Asset Management L.P. grew its stake in shares of Health Catalyst by 72.8% in the second quarter. Point72 Asset Management L.P. now owns 2,397,256 shares of the company’s stock worth $29,966,000 after purchasing an additional 1,010,356 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Health Catalyst by 12.0% during the third quarter. Vanguard Group Inc. now owns 5,941,658 shares of the company’s stock valued at $57,634,000 after acquiring an additional 636,395 shares in the last quarter. Primecap Management Co. CA lifted its stake in Health Catalyst by 86.3% in the third quarter. Primecap Management Co. CA now owns 1,120,438 shares of the company’s stock worth $11,339,000 after acquiring an additional 519,004 shares during the period. Bank of New York Mellon Corp lifted its stake in Health Catalyst by 124.0% in the third quarter. Bank of New York Mellon Corp now owns 854,896 shares of the company’s stock worth $8,652,000 after acquiring an additional 473,323 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Health Catalyst by 140.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 775,682 shares of the company’s stock valued at $9,052,000 after purchasing an additional 452,460 shares during the period. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Trading Down 2.0 %

NASDAQ:HCAT opened at $5.58 on Friday. Health Catalyst, Inc. has a 52 week low of $5.51 and a 52 week high of $14.37. The stock has a market cap of $326.76 million, a price-to-earnings ratio of -2.66 and a beta of 1.29. The company’s 50 day moving average price is $7.80 and its 200-day moving average price is $8.41. The company has a quick ratio of 4.42, a current ratio of 4.42 and a debt-to-equity ratio of 0.62.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.06. Health Catalyst had a negative return on equity of 12.19% and a negative net margin of 39.92%. The firm had revenue of $75.08 million during the quarter, compared to analysts’ expectations of $73.67 million. On average, equities research analysts forecast that Health Catalyst, Inc. will post -0.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on HCAT shares. Canaccord Genuity Group dropped their target price on shares of Health Catalyst from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, February 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a report on Wednesday, April 10th. Evercore ISI decreased their price target on shares of Health Catalyst from $11.00 to $10.00 and set an “outperform” rating for the company in a research note on Friday, February 23rd. Piper Sandler reissued an “overweight” rating and set a $15.00 price objective (down previously from $17.00) on shares of Health Catalyst in a research note on Friday, February 23rd. Finally, Guggenheim upgraded shares of Health Catalyst from a “neutral” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Friday, January 26th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.10.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.